Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome

被引：5

作者：

del-Pino, Rodrigo Aguirre ^{[1
,2
]}

Monahan, Rory C. ^{[1
,3
]}

Huizinga, Tom W. J. ^{[1
]}

Eikenboom, Jeroen ^{[4
]}

Steup-Beekman, Gerda M. ^{[1
,5
]}

机构：

[1] Leiden Univ Med Ctr, Dept Rheumatol, Leiden, Netherlands

[2] A Coruna Univ Hosp CHUAC, Div Rheumatol, Xubias Arriba 84, Galicia 15006, Spain

[3] Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands

[4] Leiden Univ Med Ctr, Dept Internal Med, Div Thrombosis & Hemostasis, Leiden, Netherlands

[5] Haaglanden Med Ctr, Dept Rheumatol, The Hague, Netherlands

来源：

SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2024年 / 50卷 / 06期

关键词：

antiphospholipid syndrome; antiphospholipid antibody; thrombosis; risk factor; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; VENOUS THROMBOEMBOLISM; SYNDROME SCORE; FOLLOW-UP; VITAMIN-D; CLASSIFICATION CRITERIA; CARDIOVASCULAR-DISEASE; CLINICAL-SIGNIFICANCE; RHEUMATOID-ARTHRITIS;

D O I：

10.1055/s-0043-1776910

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple elements are involved in the pathomechanism of aPL development and aPL-related thrombosis such as genetics, malignancy, and infections. This review will address the role of both well-known risk factors and their evolution, and of emerging risk factors, including COVID-19, in the development of aPL and thrombosis in aPL carriers.

引用

页码：817 / 828

页数：12

共 50 条

[41] Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome
Feng, Weimin
Qiao, Jiao
Tan, Yuan
Liu, Qi
Wang, Qingchen
Yang, Boxin
Yang, Shuo
Cui, Liyan
FRONTIERS IN IMMUNOLOGY, 2024, 15
[42] Antiphospholipid Antibodies and the Antiphospholipid Syndrome: From Coagulation to the Clinic
Selby, Rita
Abdulrehman, Jameel
JOURNAL OF APPLIED LABORATORY MEDICINE, 2022, 7 (01): : 373 - 378
[43] Recent Developments in Antiphospholipid Antibodies and the Antiphospholipid Syndrome Preface
Urbanus, Rolf T.
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2018, 44 (05): : 417 - 418
[44] Antiphospholipid antibodies in systemic lupus erythematosus and the antiphospholipid syndrome
Setty, YN
Komatireddy, GR
FRONTIERS IN BIOSCIENCE, 2001, 6 : E207 - E212
[45] ROLE OF ANTIPHOSPHOLIPID ANTIBODIES IN THE PATHOGENESIS OF THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME
TAKI, M
IKEDA, Y
HANDA, M
YAMAMOTO, M
WATANABE, K
MATSUO, S
MEGURO, T
YAMADA, K
ACTA HAEMATOLOGICA JAPONICA, 1990, 53 (08): : 1620 - 1629
[46] Antiphospholipid syndrome, antiphospholipid antibodies and solid organ transplantation
Gonzalez-Moreno, J.
Callejas-Rubio, J. L.
Rios-Fernandez, R.
Ortego-Centeno, N.
LUPUS, 2015, 24 (13) : 1356 - 1363
[47] Fetal death and antiphospholipid syndrome without antiphospholipid antibodies
Campoverde, JC
Marchese, ES
Cruz, EF
REVISTA CLINICA ESPANOLA, 2005, 205 (02): : 93 - 94
[48] BINDING CHARACTERISTICS OF ANTIPHOSPHOLIPID ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME AND SYPHILIS
FORASTIERO, RR
MARTINUZZO, ME
VRDOLJAK, L
CARRERAS, LO
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1274 - 1274
[49] Evaluation of the different antiphospholipid antibodies for the diagnosis of antiphospholipid syndrome
Kaushik, P
Malaviya, AN
Al-Attiya, R
Moussa, M
Das, KC
MEDICAL PRINCIPLES AND PRACTICE, 1999, 8 (04) : 315 - 321
[50] Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome?
Galli, M
HAEMOSTASIS, 2000, 30 : 57 - 62

← 1 2 3 4 5 →